Windtree Therapeutics Stock Scheduled to Split on Friday, November 25th (NASDAQ:WINT)

Shares of Windtree Therapeutics, Inc. (NASDAQ:WINTGet Rating) are going to split on Friday, November 25th. The 2-1 split was announced on Friday, November 25th. The newly issued shares will be distributed to shareholders after the closing bell on Friday, November 25th.

Windtree Therapeutics Stock Down 4.6 %

Windtree Therapeutics stock opened at $0.17 on Wednesday. The firm has a market cap of $5.06 million, a price-to-earnings ratio of -0.11 and a beta of 0.24. The stock has a fifty day simple moving average of $0.25 and a two-hundred day simple moving average of $0.38. Windtree Therapeutics has a 12 month low of $0.15 and a 12 month high of $1.78. The company has a current ratio of 2.54, a quick ratio of 2.54 and a debt-to-equity ratio of 0.86.

Analyst Upgrades and Downgrades

Separately, Oppenheimer reduced their target price on Windtree Therapeutics to $2.00 in a report on Thursday, November 17th.

Institutional Trading of Windtree Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Envestnet Asset Management Inc. grew its holdings in shares of Windtree Therapeutics by 894.7% in the third quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock worth $32,000 after acquiring an additional 96,515 shares during the period. Virtu Financial LLC grew its holdings in shares of Windtree Therapeutics by 559.5% in the third quarter. Virtu Financial LLC now owns 100,808 shares of the company’s stock worth $30,000 after acquiring an additional 85,522 shares during the period. PVG Asset Management Corp bought a new stake in shares of Windtree Therapeutics in the third quarter worth $56,000. Millennium Management LLC grew its holdings in shares of Windtree Therapeutics by 411.1% in the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after acquiring an additional 64,232 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Windtree Therapeutics by 54.1% in the second quarter. Renaissance Technologies LLC now owns 361,395 shares of the company’s stock worth $151,000 after acquiring an additional 126,949 shares during the period. Institutional investors own 5.12% of the company’s stock.

Windtree Therapeutics Company Profile

(Get Rating)

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension.

Further Reading

Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.